<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">The chest computed tomography (CT) scan on the 9th day after MSC transplantation revealed that ground-glass opacity and inflammation of pneumonia were significantly decreased. MSCsâ€™ gene expression profile shows that they were negative with ACE2 and type-2 transmembrane serine protease (TMPRSS2), suggesting that MSCs are free of SARS-CoV-2 infection. The intravenous transplantation of MSCs was, therefore, not only effective but also safe for the treatment of patients with COVID-19 pneumonia, especially patients under critically severe conditions (
 <xref rid="bib76" ref-type="bibr">Leng et al., 2020</xref>). However, additional studies are required in a more number of patients to validate this therapeutic intervention further.
</p>
